No Data
AstraZeneca PLC ADR Outperforms Market On Strong Trading Day
This article was automatically generated by MarketWatch using technology from Automated Insights. The AstraZeneca PLC ADR AZN advanced 3.80% to $66.90 Friday, on what proved to be an all-around great
What Are Whales Doing With AstraZeneca
Someone with a lot of money to spend has taken a bearish stance on AstraZeneca (NASDAQ:AZN). And retail traders should know. We noticed this today when the big position showed up on publicly available
AstraZeneca-Merck & Co's Lynparza Receives EU Panel's Positive Opinion for New Indication
11:44 AM EDT, 06/24/2022 (MT Newswires) -- The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for a new indication for AstraZeneca (AZN.L) and Me
AstraZeneca's Lynparza gets EMA panel nod for expanded use in breast cancer subtype
A panel of the European Medicines Agency (EMA) recommended the expanded approval of AstraZeneca's (NASDAQ:AZN) blockbuster cancer drug Lynparza. The EMA's Committee for Medicinal Products for Human Us
AstraZeneca, Daiichi Sankyo breast cancer drug Enhertu gets EMA panel nod for early setting use
A committee of the European Medicines Agency (EMA) recommended a change to the indication of AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's (OTCPK:DSKYF) (OTCPK:DSNKY) breast cancer drug Enhertu. The E
AstraZeneca PLC ADR Rises Thursday, Still Underperforms Market
This article was automatically generated by MarketWatch using technology from Automated Insights. The AstraZeneca PLC ADR AZN rallied 1.42% to $64.45 Thursday, on what proved to be an all-around posi
AstraZeneca's ALXN1840 Shows Promising Action Against Copper Metabolism Disorder
AstraZeneca Plc (NASDAQ:AZN) announced detailed results from the positive FoCus Phase 3 trial of ALXN1840 in Wilson's disease, an inherited condition in which the body's pathway for removing excess co
AstraZeneca Wilson disease candidate further demonstrates copper removal from tissues
AstraZeneca (NASDAQ:AZN) said its candidate for Wilson disease, ALXN1840, showed three times greater removal of copper from tissues compared to the standard of care. Detailed results from the FoCus ph
AstraZeneca Drug Candidate to Treat Wilson Disease Meets Primary Endpoint in Phase 3 Trial
09:49 AM EDT, 06/23/2022 (MT Newswires) -- AstraZeneca (AZN) said Thursday that its phase 3 trial of ALXN1840 to treat Wilson disease met its primary endpoint, demonstrating three-times greater copper
AstraZeneca's Investigational Drug Meets Primary Endpoint for Wilson Disease
08:55 AM EDT, 06/23/2022 (MT Newswires) -- AstraZeneca (AZN.L) reported Thursday results from the phase 3 trial of its ALXN1840 in which the investigational drug was able to meet the primary endpoint
Loading...